Vasopharm Raises $6.5 mill For Phase III-Ready Traumatic Brain Injury Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
The tiny German biotech, vasopharm, aims to maximize the attractiveness of its NO-synthase inhibitor for potential partners, and to keep the flag flying for nitric oxide research.
You may also be interested in...
Naproxcinod Must Show More Data On Both Safety And Therapeutic Benefit After "Complete Response" Letter
FDA tells NicOx it wants long-term studies on drug's cardiovascular and gastrointestinal safety, but no additional efficacy trials.
NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate
Deal shows - once again - that all is not lost when Big Pharma hands back a product
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.